PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism

Cardiovascular Research

Volumn 93, Issue 1, 2012, Pages 200-209

  Carnevale, Daniela ^a   Vecchione, Carmine ^a   Mascio, Giada ^a   Esposito, Giovanni ^b   Cifelli, Giuseppe ^a   Martinello, Katiuscia ^a,c   Landolfi, Alessandro ^a   Selvetella, Giulio ^a   Grieco, Paolo ^b   Damato, Antonio ^a   Franco, Elio ^a   Haase, Hannelore ^d   Maffei, Angelo ^a   Ciraolo, Elisa ^e   Fucile, Sergio ^a,c   Frati, Giacomo ^a   Mazzoni, Orazio ^b   Hirsch, Emilio ^e   Lembo, Giuseppe ^a,f  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e UNIVERSITY OF TURIN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Blood pressure; L type calcium channel; Myogenic tone; Phosphoinositide 3 kinase ; Resistance artery

Indexed keywords

CALCIUM CHANNEL L TYPE; NIFEDIPINE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CALCIUM TRANSPORT; CELL MEMBRANE; CLINICAL CHEMISTRY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME INHIBITORS; HYPERTENSION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; THIAZOLIDINEDIONES; VASODILATION;

EID: 84555177773     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr288     Document Type: Article

References (25)

1. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11: 329-411.
2. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. Blockade of PI3Kg suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-943. (Pubitemid 41294438)
3. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. PI3Kg inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11:933-935. (Pubitemid 41294437)
4. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S et al. Phosphoinositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006;103:19866-19871. (Pubitemid 46037522)
5. Siragusa M, Katare R, Meloni M, Damilano F, Hirsch E, Emanueli C et al. Involvement of phosphoinositide 3-kinase g in angiogenesis and healing of experimental myocardial infarction in mice. Circ Res 2010;106:757-768.
6. Fougerat A, Gayral S, Gourdy P, Schambourg A, Rückle T, Schwarz MK et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-g reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 2008; 117:1310-1317. (Pubitemid 351365672)
7. Damilano F, Franco I, Perrino C, Schaefer K, Azzolino O, Carnevale D et al. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase g activity in pressure overload-induced cardiac failure. Circulation 2011;123:391-399.
8. Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kg. J Exp Med 2005;201:1217-1228. (Pubitemid 40629066)
9. Costa C, Barberis L, Ambrogio C, Manazza AD, Patrucco E, Azzolino O et al. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase g. Proc Natl Acad Sci USA 2007;104: 14354-14359. (Pubitemid 350003265)
10. Zacchigna L, Vecchione C, Notte A, Cordenonsi M, Dupont S, Maretto S et al. Emilin1 links TGF-b maturation to blood pressure homeostasis. Cell 2006;124: 929-942. (Pubitemid 43344234)
11. Macrez N, Mironneau C, Carricaburu V, Quignard JF, Babich A, Czupalla C et al. Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca2+ channels. Circ Res 2001;89:692-699. (Pubitemid 34627069)
12. Haase H, Alvarez J, Petzhold D, Doller A, Behlke J, Erdmann J et al. Ahnak is critical for cardiac CaV1.2 calcium channel function and its b-adrenergic regulation. FASEB J 2005;19:1969-1977. (Pubitemid 41759742)
13. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-919.
14. Hill MA, Meininger GA, Davis MJ, Laher I. Therapeutic potential of pharmacologically targeting arteriolar myogenic tone. Trends Pharmacol Sci 2009;30:363-374.
15. Vecchione C, Carnevale D, Di Pardo A, Gentile MT, Damato A, Cocozza G et al. Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/bPIX/Rac-1 pathway. Hypertension 2009;54:1028-1034.
16. Le Blanc C, Mironneau C, Barbot C, Henaff M, Bondeva T,Wetzker R et al. Regulation of vascular L-type Ca2+ channels by phosphatidylinositol 3,4,5-trisphosphate. Circ Res 2004;95:300-307. (Pubitemid 39056291)
17. Viard P, Butcher AJ, Halet G, Davies A, Nürnberg B, Heblich F et al. PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat Neurosci 2004;7:939-946. (Pubitemid 39129502)
18. Catalucci D, Zhang DH, DeSantiago J, Aimond F, Barbara G, Chemin J et al. Akt regulates L-type Ca2+ channel activity by modulating Cava1 protein stability. J Cell Biol 2009;184:923-933.
19. Quignard JF, Mironneau J, Carricaburu V, Fournier B, Babich A, Nurnberg B et al. Phosphoinositide 3-kinase g mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J Biol Chem 2001;276:32545-32551.
20. Patel A, Sharif-Naeini R, Folgering JR, Bichet D, Duprat F, Honoré E. Canonical TRP channels and mechanotransduction: from physiology to disease states. Pflugers Arch 2010;460:571-581.
21. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002;110:737-749. (Pubitemid 35283963)
22. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD et al. Genomewide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011;43:1005-1011. doi: 10.1038/ng.922.
23. Cohuet G, Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther 2006;111:81-98. (Pubitemid 43765539)
24. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-1587. (Pubitemid 43739417)
25. Brophy JM. Cardiovascular risk associated with celecoxib. N Engl J Med 2005;352: 2648-2650.